ライフサイエンスコーパス: P450

1 etabolizing enzymes of the cytochrome P450s (P450).

2 electron transport from NADPH to cytochrome P450.

3 of an experimental structure of this unique P450.

4 c expression of a gene encoding a cytochrome P450.

5 mega-hydroxylation are conserved in family 4 P450s.

6 The enzyme cytochrome P450 11A1 cleaves the C20-C22 carbon-carbon bond of chol

7 22R-dihydroxycholesterol intermediate of the P450 11A1 reaction to produce the key steroid pregnenolo

8 P450 11A1 was incubated with 20R,22R-dihydroxycholestero

9 The mechanisms of P450s 11A1, 17A1, 19A1, and 51A1 have been controversial

10 Aldosterone synthase (AS, cytochrome P450 11B2, cyp11B2) is the sole enzyme responsible for t

11 he clinical utility of inhibiting cytochrome P450 17A1 (CYP17), a cytochrome p450 enzyme that is requ

12 Cytochrome P450 17A1 (CYP17A1) is an important target in the treatm

13 arity of the crystal structures of zebrafish P450 17A1 and 17A2 and human P450 17A1.

14 These P450 17A1 and 17A2 mutants had catalytic profiles more s

15 nenolone 17alpha,20-lyase reactions of human P450 17A1 and found incorporation of one (18)O atom (fro

16 Human P450 17A1 and zebrafish P450s 17A1 and P450 17A2 readily

17 ed from pregnenolone did not dissociate from P450 17A1 before conversion to DHEA.

18 r groups of reactions, indicating that human P450 17A1 is an inherently distributive enzyme but that

19 lso crystallized this five-residue zebrafish P450 17A1 mutant, and the active site still resembled th

20 Human P450 17A1 reaction rates examined are enhanced by the ac

21 Steroid binding to P450 17A1 was more complex than a simple two-state syste

22 sults also suggest multiple conformations of P450 17A1, as previously proposed on the basis of NMR sp

23 ochrome b5 (b5), but the exact role of b5 in P450 17A1-catalyzed reactions is unclear as are several

24 es of zebrafish P450 17A1 and 17A2 and human P450 17A1.

25 Human P450 17A1 and zebrafish P450s 17A1 and P450 17A2 readily converted these to the

26 Cytochrome P450 (P450) 17A1 catalyzes the oxidations of progesterone and

27 Zebrafish P450 17A2 catalyzes only the 17alpha-hydroxylations.

28 We conclude that zebrafish P450 17A2 is capable of lyase activity with the 17alpha-

29 Human P450 17A1 and zebrafish P450s 17A1 and P450 17A2 readily converted these to the lyase products

30 the linkage between inhibition of cytochrome P450 19A aromatase (the MIE) and population-level decrea

31 le-3-carbinol (I3C)-inducible rat cytochrome P450 1A1 promoter.

32 augments several P450 activities, inhibited P450 21A2 activity.

33 2 variants ranged from 0.00009% to 30% of WT P450 21A2 and the extent of heme incorporation from 10%

34 V-visible and CD spectroscopy, we found that P450 21A2 thermal stability assessed in bacterial cells

35 Twelve P450 21A2 variants associated with either salt-wasting o

36 effects (>/= 5.5) were observed for all six P450 21A2 variants examined for 21-hydroxylation of 21-d

37 Our in-depth investigation of CAH-associated P450 21A2 variants reveals critical insight into the eff

38 previously reported a structure of WT human P450 21A2 with bound progesterone and now present a stru

39 iants were 37-13,000-fold higher than for WT P450 21A2.

40 s impaired in mice lacking either cytochrome P450 26B1 (Cyp26b1), which results in excess RA, or reti

41 Cytochrome P450 27A1 (CYP27A1 or sterol 27-hydroxylase) is a ubiqui

42 Cytochrome P450 27A1 (CYP27A1) is a ubiquitous enzyme that hydroxyl

43 We show by proteomic analysis that P450 27C1 is localized to human skin, with two proteins

44 P450 27C1 oxidized all-trans-retinol to 3,4-dehydroretin

45 Ferric P450 27C1 reduction by adrenodoxin was 3-fold faster in

46 cently, zebrafish and human cytochrome P450 (P450) 27C1 enzymes have been shown to be retinoid 3,4-de

47 of fluorescently labeled CPR and cytochrome P450 2C9 (CYP2C9) molecules in which stochastic analysis

48 Cytochrome P450-2E1 (CYP2E1) increases oxidative stress.

49 Cytochrome P450 3A (CYP3A) is the most abundant CYP450 enzyme in th

50 conformational landscape of human cytochrome P450 3A4 (CYP3A4) by electron paramagnetic resonance and

51 cancer drug, in interaction with cytochrome P450 3A4 (CYP3A4) enzyme and multiwalled carbon nanotube

52 tituent alleviated time-dependent cytochrome P450 3A4 (CYP3A4) inhibition.

53 Human cytochrome P450 3A4 (CYP3A4) is a key xenobiotic-metabolizing enzym

54 Human cytochrome P450 3A4 (CYP3A4) is a major hepatic and intestinal enzy

55 Cytochrome P450 3A4 (CYP3A4) is the dominant P450 enzyme involved i

56 Inhibition of cytochrome P450 3A4 (CYP3A4), the major drug metabolizing enzyme, b

57 ions and the presence of combined cytochrome P450 3A4 and P-glycoprotein inhibitors in the Rivaroxaba

58 those treated with >/= 1 combined cytochrome P450 3A4 and P-glycoprotein inhibitors.

59 of several drugs that are largely cleared by P450 3A4.

60 nderstand the structural differences between P450s 3A4 and 3A5, the structure of 3A5 complexed with r

61 The contributions of cytochrome P450 3A5 to the metabolic clearance of marketed drugs is

62 The contribution of P450 3A5 to these clearance pathways varies between indi

63 Cytochrome P450 46A1 (CYP46A1) is a microsomal enzyme and cholester

64 Cytochrome P450 46A1 (CYP46A1, cholesterol 24-hydroxylase) is the e

65 carrying four copies of the human cytochrome P450 4A11 gene (CYP4A11) under control of its native pro

66 To this end, the structure of rabbit P450 4B1 complexed with its substrate octane was determi

67 In conclusion, P450 4B1 exhibits structural adaptations for omega-hydro

68 By the time cytochrome P450 7A1 expression is reduced these drugs may be less e

69 C57Bl/6 or cytochrome p450 7A1 knockout (Cyp7A1(-/-)) mice were fed a control,

70 llular bile salt transporters and cytochrome P450 7a1, the key regulator of bile salt synthesis, indi

71 ude an apparent lack of l-Glu binding to the P450 active site and different pathways of signal transd

72 Cytochrome b5, which augments several P450 activities, inhibited P450 21A2 activity.

73 y the effect of the two azoles on cytochrome P450 activity, measured on D. magna in vivo.

74 ts to stabilize candidates toward cytochrome P450 activity, which increases the risk for new compound

75 pathway for the signal transmission from the P450 allosteric site to the active site.

76 Surprisingly, this cytochrome P450 also catalyzes the non-oxidative isomerization of t

77 which involves a uniquely adapted cytochrome P450-amidotransferase enzyme pair and highlights the fir

78 oderately decreased activity with cytochrome P450 and cytochrome c It formed a flexible loop, which t

79 alance, including quaternary organization of P450 and diffusion-limited models.

80 , we report the discovery of five cytochrome P450s and two acetyltransferases which catalyze a cascad

81 lp explain reactivity patterns in cytochrome P450, and subsequently has been used to provide insight

82 transformation of IBP was first catalyzed by P450, and then by glycosyltransferase, followed by furth

83 Cytochrome P450s are the primary enzymes involved in phase I drug m

84 Here we provide evidence that cytochrome P450 aromatase (AROM), the enzyme converting testosteron

85 tedly regulates the expression of cytochrome P450 aromatase (P450arom).

86 orders and of the side effects of cytochrome P450 aromatase inhibitors, which are frequently used for

87 suggested that bacterial P450s, particularly P450s belonging to mycobacteria, are highly conserved bo

88 In contrast, P450 BM3 adsorbed on unmodified indium tin oxide electro

89 e morphology, charge-transfer resistance and P450 BM3 immobilization as well as activity.

90 ) calculations of the fatty acid hydroxylase P450 BM3 predict the binding mechanism of the fatty acid

91 As reference enzyme, we chose cytochrome P450 BM3 that is restricted by NADPH dependence.

92 "P411" serine-ligated variant of cytochrome P450(BM3) has been engineered to initiate a sulfimidatio

93 ernative concept based on redox catalysis by P450-BM3, leading to the same Kemp product via a fundame

94 undergoes redox-mediated Kemp elimination by P450-BM3.

95 ghout the cell, as expected for a microsomal P450, but CYP4G16 localizes to the periphery of the cell

96 a red-shifted component characteristic of a P450-carbene complex.

97 revailing mechanistic uncertainties in human P450-catalysed metabolism of the immunomodulatory drug l

98 te, inhibit, or have no effect on cytochrome P450 catalysis, often in a P450-dependent and substrate-

99 exes are relevant to the observed effects on P450 catalysis.

100 athways that are operative during cytochrome P450-catalyzed cyclopropanation.

101 c biotransformation of TBECH via cyctochrome P450-catalyzed hydroxylation, debromination, and alpha-o

102 Biosynthetic pathways involving cytochrome P450-catalyzed oxidation of fatty acids in yeast and bac

103 establishes E. coli as a tractable host for P450 chemistry, highlights the potential magnitude of pr

104 Given the relevance of this discrepancy to P450 chemistry, it is important to determine whether Pdx

105 We show that the predicted cytochrome P450 ClaM catalyzes the dimerization of nataloe-emodin t

106 fferential expression patterns of cytochrome P450 complement (CYPome) were analyzed between the susce

107 ave prepared a selenolate-ligated cytochrome P450 compound I intermediate.

108 Direct electrochemistry of cytochrome P450 containing systems has primarily focused on investi

109 enome encodes 20 cytochromes P450, including P450s crucial to infection and bacterial viability.

110 odrug-mediated utilization of the cytochrome P450 (CYP) 1A1 to obtain the selective release of potent

111 Cytochrome P450 (CYP) 1B1 is implicated in vascular smooth muscle c

112 fatRA metabolism by talarozole, a cytochrome P450 (CYP) 26 specific inhibitor, increased the effects

113 ssessment confirmed inhibition of cytochrome P450 (CYP) 2C19 and CYP3A4 by meropenem, suggesting that

114 Cytochrome P450 (CYP) 3A accounts for nearly 30% of the total CYP e

115 strated that dronedarone inhibits cytochrome P450 (CYP) 3A4 and 3A5 in a time-dependent manner.

116 e begun to uncover the effects of cytochrome P450 (CYP) 4A in TAMs on lung pre-metastatic niche forma

117 ulent Mtb H37Rv strain encodes 20 cytochrome P450 (CYP) enzymes, many of which are implicated in Mtb

118 stalk between endocannabinoid and cytochrome P450 (CYP) epoxygenase metabolic pathways.

119 Cytochrome P450 (CYP) family members are known to be present in the

120 dition, the expression of several cytochrome P450 (CYP) genes were also modified in both fungi by MP4

121 ated fatty acids derived from the cytochrome P450 (CYP) monooxygenase pathway serve as vital second m

122 Cytochrome P450 (CYP)1A enzymes are protective against hyperoxic lu

123 ioxin (TCDD) on the expression of cytochrome P450 (CYP)1A1 and cytokines in various tissues of mice.

124 e most up-regulated genes include cytochrome P450s (CYP) CYP6P9a, CYP6P9b and CYP6M7.

125 Cytochrome P450 (P450, CYP) 17A1 plays a critical role in steroid metabol

126 Cytochrome P450 (P450, CYP) 21A2 is the major steroid 21-hydroxylase, con

127 Multiple cytochrome P450 (CYP1A1, CYP2A19 and CYP2C36) genes displayed diffe

128 Cytochrome P450 CYP26 enzymes are responsible for all-trans-retinoi

129 Although the cytochrome P450 CYP27B1 plays a critical role in vitamin D biology,

130 Additionally, inhibition of human cytochrome P450 (CYP450) by NSC23925b was examined in vitro.

131 s in the MG, including members of cytochrome P450 (CYP450) family and genes involved in fatty acid be

132 Intracellular enzymes, such as cytochrome P450 (CYP450), have also been suggested to contribute.

133 Malassezia globosa cytochromes P450 CYP51 and CYP5218 are sterol 14alpha-demethylase (t

134 OCHRON1 (ZmPLA1) gene, encoding a cytochrome P450 (CYP78A1), results in increased organ growth, seedl

135 Cytochromes P450 (CYPs) play a key role in generating the structural

136 her tyrosine hydroxylase (TH) and cytochrome P450s (CYPs) catalyzed this process.

137 Characterization of the cytochrome P450s (CYPs) identified from these loci enabled us to un

138 sed to identify the binding interface of the P450-cytb5 complex in the nanodisc.

139 of full-length mammalian 72-kDa cytochrome P450-cytochrome b5 complex in lipid bilayers.

140 urine hepatocytes contain an expanded set of P450 cytochromes that form the major class of drug-metab

141 cal development, but express residual murine p450 cytochromes.

142 otein vital for the regulation of cytochrome P450 (cytP450) metabolism and is capable of electron tra

143 ect on cytochrome P450 catalysis, often in a P450-dependent and substrate-dependent manner that is no

144 Here we report that P450s derived from a thermophilic organism and containin

145 ion that disrupts the BC-loop regions at the P450 dimer interface and results in a CYP126A1 monomeric

146 Mycobacteria possess the highest P450 diversity percentage compared to other microbes and

147 The role of cytochrome P450 drug metabolizing enzymes in the efficacy of tamoxi

148 that changes in the production of cytochrome P450 eicosanoids alter BP.

149 arizes the emerging evidence that cytochrome P450 eicosanoids have a role in the pathogenesis of hype

150 d (20-HETE), one of the principle cytochrome P450 eicosanoids, is a potent vasoactive lipid whose vas

151 ethod was used to compare general cytochrome P450 enzyme activity by monitoring the transformation of

152 ive to adults may be due to lower cytochrome P450 enzyme activity in fat bodies.

153 re we report the engineering of a cytochrome P450 enzyme by directed evolution to catalyze metal-oxo-

154 In particular, variants of the P450 enzyme CYP119 containing iridium in place of iron c

155 transcriptionally regulating the cytochrome P450 enzyme Cyp1b1 Furthermore, expression of its close

156 D3), occurs in the kidney via the cytochrome P450 enzyme CYP27B1.

157 CYP121 is a cytochrome P450 enzyme from Mycobacterium tuberculosis that catalyz

158 CYP121, the cytochrome P450 enzyme in Mycobacterium tuberculosis that catalyzes

159 Cytochrome P450 3A4 (CYP3A4) is the dominant P450 enzyme involved in human drug metabolism, and its i

160 14alpha-demethylase (CYP51) is a cytochrome P450 enzyme required for biosynthesis of sterols in euka

161 azole compounds that inhibit the cytochrome P450 enzyme sterol 14alpha-demethylase.

162 zation of vinorine hydroxylase, a cytochrome P450 enzyme that hydroxylates vinorine to form vomilenin

163 g cytochrome P450 17A1 (CYP17), a cytochrome p450 enzyme that is required for the production of andro

164 he desired outcome, an engineered cytochrome P450 enzyme was employed to effect a chemo- and regiosel

165 egions contains a gene encoding a cytochrome P450 enzyme, CYP2J19.

166 WCNTs) with the drug-metabolizing cytochrome P450 enzyme, CYP3A4.

167 f the cell membrane, a unique position for a P450 enzyme.

168 NMR results revealed that P450 enzymes bound to either b5 alpha4-5 (CYP2A6 and CYP

169 uisitely engineered myoglobin and cytochrome P450 enzymes can generate these complexes and facilitate

170 n expansion of the activities carried out by P450 enzymes distinct from oxygen insertion.

171 metabolism of arachidonic acid by cytochrome P450 enzymes emerged.

172 p450 enzymes exhibit C-H oxidation site-selectivity, in

173 Although the traditional mechanism for P450 enzymes has been well studied, it is unclear whethe

174 Cytochrome P450 enzymes have been engineered to catalyze abiologica

175 imilar to the substrates of other cytochrome P450 enzymes involved in steroidogenesis, and interferen

176 Cytochrome P450 enzymes of the CYP720B subfamily play a central rol

177 steroidogenesis, human microsomal cytochrome P450 enzymes require the sequential input of two electro

178 iswhen CYP125A1 and CYP142A1, the cytochrome P450 enzymes that initiate degradation of the sterol sid

179 esis, including ABC transporters, cytochrome P450 enzymes, and an acyltransferase.

180 rfaces are responsible for binding different P450 enzymes, but that these different complexes are rel

181 compound is a potent inhibitor of cytochrome P450 enzymes, probably due to a 4-pyridyl substituent.

182 the redox partner for most human cytochrome P450 enzymes.

183 cting with different human drug-metabolizing P450 enzymes.

184 ith three to four modifying Cytochrome P450 (P450) enzymes that are responsible for cyclizing bound p

185 st, pharmacological inhibition of cytochrome P450 epoxygenases opened the myocardial mPTP in human he

186 subfamily E member 1 (CYP2E1) and cytochrome P450 family 1 subfamily A member 2 (CYP1A2) that convert

187 henotypic associations related to Cytochrome P450 Family 2 Subfamily A Member 6 (CYP2A6), we investig

188 ibited higher basal expression of cytochrome P450 family 2 subfamily E member 1 (CYP2E1) and cytochro

189 e genes, 25(OH)D3-24-hydroxylase (cytochrome P450 family 24 subfamily A member 1) mRNA expression is

190 l of 25(OH)D3-1alpha-hydroxylase (cytochrome P450 family 27 subfamily B member 1), and there is no de

191 P450 family 4 fatty acid omega-hydroxylases preferential

192 Enzymes belonging to the cytochrome P450 family have an essential role in creating the immen

193 CYP126A1 is representative of a P450 family widely distributed in mycobacteria and other

194 dependent on hepatic induction of cytochrome P450, family 7, subfamily b, polypeptide 1 (CYP7B1) and

195 astatin nor pravastatin depend on cytochrome P450 for primary metabolism.

196 changes occurred at clinical disease onset (P450) for S and FR MU.

197 These enzymes include two cytochromes P450 from the CYP71 clan and an alcohol dehydrogenase (A

198 llum of cholesterol/cholestanol-metabolizing P450s from a pool of metabolically available cholestanol

199 or alone including alterations of cytochrome P450 function, retinoid metabolism, and nicotine catabol

200 BMAL-, and aryl hydrocarbon receptor-induced P450 gene expression and BaP metabolism was similar to B

201 Expansion of the cytochrome P450 gene family is often proposed to have a critical ro

202 investigated the function of the cytochrome P450 gene LmCYP4G102 in the migratory locust Locusta mig

203 ysis identified overexpression of cytochrome P450 genes as the main mechanism driving this resistance

204 Previous studies revealed that two P450 genes, CYP9M10 and CYP6AA7, are not only up-regulat

205 dition to up-regulating multiple detoxifying P450 genes, quercetin is a negative transcriptional regu

206 ifferentiation, including hCYP19A1/aromatase P450, glial cells missing 1 (GCM1), frizzled 5 (FZD5), W

207 tion of cytochrome P450 monooxygenases (CYPs/P450s), great progress has been made in understanding th

208 o other microbes and have a high coverage of P450s (>/=1%) in their genomes, as found in fungi and pl

209 from the axial thiolate ligand of cytochrome P450 has been proposed to increase the reactivity of com

210 Subsequently, deletion of two cytochromes P450 in the dynemicin cluster suggested that the dynemic

211 A minimal set of three P450s in combination with a single acetyl transferase wa

212 from its most closely related sterol-binding P450s in M. tuberculosis, suggesting that further invest

213 However, the molecular evolution of P450s in terms of their dynamics both at protein and DNA

214 The enzyme is unusual among mammalian P450s in that the predominant oxidation is a desaturatio

215 irect assays of interaction and reduction of P450s in vitro, however, showed that both classes of CPR

216 Cytochrome P450 monooxygenases (P450) in the honey bee, Apis mellifera, detoxify phytoch

217 rculosis H37Rv genome encodes 20 cytochromes P450, including P450s crucial to infection and bacterial

218 metabolic stability and reducing cytochrome P450 inhibition driven drug-drug interaction concerns to

219 ity in human liver microsomes and cytochrome P450 inhibition potential.

220 response were ameliorated by the cytochrome P450 inhibitor aminobenzotriazole.

221 he tightest-binding azaheterocycles found in P450 inhibitors and could offer new avenues for inhibito

222 entified six triazole fungicides, all fungal P450 inhibitors, that dock in the catalytic site.

223 4) devoid of antifungal and human cytochrome P450 inhibitory activity with excellent pharmacokinetics

224 This P450 is also a potential target for Alzheimer disease be

225 Oxidative enzymes such as cytochrome P450 isozymes are rapidly upregulated in TG neurons afte

226 romosome 8, close to a cluster of cytochrome P450 loci (CYP2J2-like) that are candidates for caroteno

227 s unclear whether CYP121 follows the general P450 mechanism or uses a different catalytic strategy fo

228 Whereas in the generally accepted P450 mechanism, binding of the primary substrate in the

229 NMP is primarily detoxified via a cytochrome P450 mediated pathway.

230 glycosylation, selective in vitro cytochrome P450-mediated oxidation, and chemical oxidation was used

231 rug interactions due to competing cytochrome P450 metabolism between statins and commonly used antire

232 Using a LC-MS method, putative cytochrome P450 metabolites of NMP were identified and quantified i

233 Several P450s metabolize quercetin in adult workers.

234 redox enzyme which is a key component of the P450 mono-oxygenase drug-metabolizing system.

235 PEN2 substrate production by the cytochrome P450 monooxygenase CYP81F2 is localized to the surface o

236 Cytochrome P450 monooxygenase was involved in the production of the

237 ing enzymatic catalyst-based on a cytochrome P450 monooxygenase-for the highly enantioselective inter

238 ors of the important enzyme class cytochrome P450 monooxygenases (CYPs), thereby influencing the deto

239 nce the initial identification of cytochrome P450 monooxygenases (CYPs/P450s), great progress has bee

240 Cytochrome P450 monooxygenases (P450) in the honey bee, Apis mellif

241 more than half (51.2%) of the CBP cytochrome P450 monooxygenases (P450s) that are up-regulated in the

242 arge repertoire of genes encoding cytochrome P450 monooxygenases and glutathione S-transferases assoc

243 While CYP81Fs encoding cytochrome P450 monooxygenases and IGMTs encoding indole glucosinol

244 expressed genes (DEGs), including cytochrome P450 monooxygenases and UDP-glycosyltransferases, was sh

245 Cytochrome P450 monooxygenases CYP101A1 and MycG catalyze regio- an

246 is demonstrated for both ammonia lyases and P450 monooxygenases expressed within live bacterial colo

247 Cytochrome P450 monooxygenases play a critical role in insecticide

248 e Jeotgalicoccus sp. peroxygenase cytochrome P450 OleTJE (CYP152L1) is a hydrogen peroxide-driven oxi

249 and the omega-6 lipid products of cytochrome P450 oxidase 2C promote neovascularization in both the r

250 l replicas of the peroxidases and cytochrome P450 oxidizing enzymes.

251 nerated a conditional knock-out of the NADPH-P450 oxidoreductase (Por) gene combined with Il2rg (- /-

252 Human NADPH-cytochrome P450 oxidoreductase (POR) gene mutations are associated

253 Plant P450s receive electrons from NADPH P450 oxidoreductase (POR) to orchestrate the bio-synthes

254 te that the catalytic activity of cytochrome P450 oxidoreductase is a function of the length, sequenc

255 uction by the redox partner NADPH-cytochrome P450 oxidoreductase, and the amount of P450 reduced.

256 Here we delete in a moss the P450 oxygenase that defines the entry point in angiosper

257 Cytochrome P450 (P450) 17A1 catalyzes the oxidations of progesteron

258 Recently, zebrafish and human cytochrome P450 (P450) 27C1 enzymes have been shown to be retinoid

259 ting with three to four modifying Cytochrome P450 (P450) enzymes that are responsible for cyclizing b

260 Cytochrome P450 (P450, CYP) 17A1 plays a critical role in steroid m

261 Cytochrome P450 (P450, CYP) 21A2 is the major steroid 21-hydroxylas

262 drug-metabolizing enzymes of the cytochrome P450s (P450).

263 me derivatives, we have evolved a cytochrome P450 (P450BM3) that selectively incorporates a nonprotei

264 Results suggested that bacterial P450s, particularly P450s belonging to mycobacteria, are

265 icosatrienoic acids (EETs) produced from the P450 pathway are angiogenic, inducing cancer tumor growt

266 inflammatory metabolites from the cytochrome P450 pathway were reduced in cART/HIV-1-exposed infants.

267 Many family 4 cytochrome P450s play key roles in fatty acid hydroxylation at the

268 sm-an alcohol dehydrogenase and a cytochrome P450-produces unexpected rearrangements in strictosidine

269 ll genes encoding heme-containing cytochrome P450 proteins.

270 Plant P450s receive electrons from NADPH P450 oxidoreductase (

271 hrome P450 oxidoreductase, and the amount of P450 reduced.

272 were separately co-expressed with cytochrome P450 reductase (CPR) in insect Spodoptera frugiperda (Sf

273 Cytochrome P450 reductase (CPR) is the redox partner for most human

274 type I nitroreductase (TbNTR) or cytochrome P450 reductase (TbCPR) dependent prodrugs that, followin

275 NADPH-cytochrome P450 reductase is a multi-domain redox enzyme which is a

276 ase, glutathione reductase, NADPH-cytochrome P450 reductase, biliverdin reductase, and thioredoxin re

277 ivered by the FMN domain of NADPH-cytochrome P450 reductase.

278 Cytochrome P450-reductase (CPR) is a versatile NADPH-dependent elec

279 ketide synthases, hydrolases, and cytochrome P450s related to known fatty acid hydroxylases.

280 Many M. tuberculosis P450s remain uncharacterized, suggesting that their furt

281 ial import of cytochrome P450scc (cytochrome P450 side chain cleavage enzyme) and aldosterone synthas

282 olenic acid, respectively) in the cytochrome P450/soluble epoxide hydrolase pathway.

283 Cytochrome P450 superfamily proteins play important roles in detoxi

284 for substrate binding and recognition in the P450 superfamily.

285 arin deactivation via the hepatic cytochrome P450 system.

286 It is also a prelude for driving plant P450 systems electronically for simplified and cost-effe

287 biosynthesis, by showing that the cytochrome P450 TgCYP76AE2, transiently expressed in Nicotiana bent

288 A1, an important brain enzyme and cytochrome P450 that could be activated pharmacologically.

289 ) of the CBP cytochrome P450 monooxygenases (P450s) that are up-regulated in the R strain are also in

290 Similar to cytochromes P450, the buildup of I435 occurs in nitric oxide synthas

291 lized by cyclooxygenase (COX) and cytochrome P450 to produce proangiogenic metabolites.

292 e nature's favored oxygenase, the cytochrome P450, to perform high-level oxygenation chemistry in Esc

293 Additionally, 16 cytochrome P450 transcripts related to secondary metabolism were al

294 nitration processes driven by an engineered P450 TxtE fusion construct.

295 ectrochemistry of non-engineered cytochromes P450 under native-like conditions.

296 In vitro experiments with purified P450s were conducted as well.

297 This indicated that these P450s were involved in the greater rate of metabolism of

298 cket of CYP9Q1, a broadly substrate-specific P450 with high quercetin-metabolizing activity, identifi

299 r to introduce decarboxylation activity into P450s with different substrate preferences.

300 reaction of hemoproteins, notably cytochrome P450, with PN leads to the buildup of an intermediate sp